Status:
COMPLETED
Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Lead Sponsor:
Indiana University
Conditions:
Conscious Sedation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The standard approach to sedation in endoscopic retrograde cholangiopancreatography (ERCP) involves the use of benzodiazepines and opiates to achieve a moderate depth of sedation. There is data to sug...
Eligibility Criteria
Inclusion
- Male or female patients \>18 years of age referred to IUMC for first-time ERCP procedure.
Exclusion
- Pregnant women
- age \<18 years
- Incarcerated individuals
- Patients currently taking or having taken gabapentin or pregabalin within the last 3 months
- Patients unable to give informed consent
- Patients not able to fill out visual analog scales for pain, nausea and anxiety or unable to fill out survey regarding procedural satisfaction.
- High risk patients for anesthesia: home oxygen, class III or IV heart failure, sleep apnea (on CPAP/BiPAP at home), or ASA class \> 3.
- Patients undergoing general anesthesia for their ERCP procedure
- Patients receiving propofol sedation for their ERCP procedure
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT01143766
Start Date
April 1 2010
End Date
December 1 2011
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, Indiana University Purdue University Indianapolis
Indianapolis, Indiana, United States, 46202